| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
|
Eur J Cancer
|
2009
|
77.71
|
|
2
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
|
N Engl J Med
|
2012
|
52.99
|
|
3
|
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
|
N Engl J Med
|
2012
|
35.24
|
|
4
|
The blockade of immune checkpoints in cancer immunotherapy.
|
Nat Rev Cancer
|
2012
|
24.94
|
|
5
|
Signatures of mutational processes in human cancer.
|
Nature
|
2013
|
21.63
|
|
6
|
Optimal two-stage designs for phase II clinical trials.
|
Control Clin Trials
|
1989
|
21.03
|
|
7
|
PD-1 and its ligands in tolerance and immunity.
|
Annu Rev Immunol
|
2008
|
19.24
|
|
8
|
Nivolumab plus ipilimumab in advanced melanoma.
|
N Engl J Med
|
2013
|
17.53
|
|
9
|
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
|
Proc Natl Acad Sci U S A
|
2002
|
12.39
|
|
10
|
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
|
Nature
|
2014
|
10.49
|
|
11
|
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
|
J Clin Oncol
|
2014
|
9.86
|
|
12
|
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
|
Immunity
|
2007
|
8.94
|
|
13
|
The three Es of cancer immunoediting.
|
Annu Rev Immunol
|
2004
|
8.20
|
|
14
|
Inhibitory B7-family molecules in the tumour microenvironment.
|
Nat Rev Immunol
|
2008
|
8.17
|
|
15
|
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2010
|
5.99
|
|
16
|
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
|
Cancer Res
|
2005
|
4.94
|
|
17
|
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
|
Lancet Oncol
|
2015
|
4.63
|
|
18
|
Use of normal tissue complication probability models in the clinic.
|
Int J Radiat Oncol Biol Phys
|
2010
|
4.33
|
|
19
|
Radiation dose-volume effects in the lung.
|
Int J Radiat Oncol Biol Phys
|
2010
|
3.73
|
|
20
|
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
|
Immunol Rev
|
2008
|
3.18
|
|
21
|
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
|
Proc Natl Acad Sci U S A
|
2011
|
2.90
|
|
22
|
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.
|
Int J Radiat Oncol Biol Phys
|
2010
|
2.84
|
|
23
|
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
|
J Immunol
|
2011
|
2.69
|
|
24
|
Radiation dose-volume effects in the heart.
|
Int J Radiat Oncol Biol Phys
|
2010
|
2.66
|
|
25
|
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.
|
J Thorac Oncol
|
2013
|
2.33
|
|
26
|
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
|
J Clin Invest
|
2011
|
1.91
|
|
27
|
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.
|
Cell Death Differ
|
2013
|
1.60
|
|
28
|
Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
|
Pharm Res
|
2006
|
1.26
|
|
29
|
Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
|
Int J Oncol
|
2009
|
1.26
|
|
30
|
Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
|
J Clin Pharmacol
|
2009
|
1.25
|
|
31
|
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
|
Cancer Immunol Res
|
2015
|
1.01
|
|
32
|
Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
|
Oncoimmunology
|
2013
|
0.93
|
|
33
|
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
|
J Clin Oncol
|
2016
|
0.92
|
|
34
|
Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.
|
J Clin Pharmacol
|
2011
|
0.89
|
|
35
|
How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?
|
Lung Cancer
|
2013
|
0.85
|
|
36
|
Analysis of duration of response in oncology trials.
|
Contemp Clin Trials
|
2007
|
0.85
|
|
37
|
Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
|
J Clin Oncol
|
2017
|
0.84
|
|
38
|
Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
|
Clin Pharmacokinet
|
2013
|
0.82
|
|
39
|
Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
|
Expert Opin Biol Ther
|
2008
|
0.81
|
|
40
|
Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV.
|
Cytotherapy
|
2008
|
0.78
|
|
41
|
Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.
|
J Clin Pharmacol
|
2014
|
0.76
|
|
42
|
Radiotherapy in combination with immune checkpoint inhibitors.
|
Curr Opin Oncol
|
2017
|
0.75
|
|
43
|
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.
|
Oncoimmunology
|
2017
|
0.75
|
|
44
|
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
|
JAMA Oncol
|
2016
|
0.75
|
|
45
|
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2017
|
0.75
|
|
46
|
European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer.
|
Radiother Oncol
|
2017
|
0.75
|